Form 4: Tonix Pharmaceuticals CEO Acquires Millions in Stock Options
SEC Form 4 Filing
Tonix Pharmaceuticals CEO Seth Lederman reports the acquisition of millions of stock options with varying exercise prices and vesting schedules.
Summary
- Seth Lederman, CEO of Tonix Pharmaceuticals Holding Corp., filed a Form 4 on February 29, 2024, reporting transactions related to derivative securities.
- On February 27, 2024, Lederman acquired stock options with exercise prices of $0.368, $0.46, and $0.0368.
- The number of options acquired were 235,320, 1,903,680, and 1,309,911 respectively.
- The options have varying vesting schedules, with some vesting starting on February 27, 2025, and others on August 27, 2024.
- All options expire on February 27, 2034.
- The options were granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.
Sentiment
Score: 6
Explanation: The document is a neutral report of stock option grants. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard executive compensation practices.
Positives
- The acquisition of stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize executives and align their interests with those of shareholders.
Stakeholder Impact
- The granting of stock options could potentially impact shareholders by diluting the value of existing shares if the options are exercised.
Key Dates
| Date | Description |
|---|---|
| 02/27/2024 | Date of stock option acquisition |
| 02/27/2025 | Vesting start date for some options |
| 08/27/2024 | Vesting start date for some options |
| 02/27/2034 | Expiration date for all options |
| 02/29/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.